What Dafalgan Codeine (Acetaminophen/Codeine) Treats: Main Uses and Benefits

This combination is generally used to address symptoms related to physical discomfort that fall within the mild to moderate range of intensity. It is commonly applied in clinical settings that involve acute or unstable symptom patterns, such as pain following a minor procedure, sudden post-traumatic discomfort, or episodic conditions like severe menstrual cramps. The combination is commonly used across conditions presenting with acute episodes characterized by mild to moderate pain.

The therapeutic scope is relevant for managing symptom clusters that may become intense or disruptive, specifically including elevated body temperature and a persistent or irritating cough, when these symptoms occur together. This helps address conditions where symptoms may intensify temporarily, providing supportive relief in situations where additional management of discomfort is required. The primary benefit is that the temporary assistance is relevant for easing distress and contributes to improved comfort during periods of heightened symptoms.

---

Therapeutic Scope Summary

Therapeutic Scope: Management of Symptoms Related to Mild to Moderate Pain, Fever, and Disruptive Cough

Regulatory References

1. NIH MedlinePlus Drug Information

The eligibility for the Acetaminophen and Codeine combination product is strictly defined by regulatory authorities and centers on potential risks from the Codeine component.

Absolute Contraindications (Must Not Be Used)

Use is formally contraindicated for all children younger than 12 years of age for any indication, and for pediatric patients under 18 following tonsillectomy or adenoidectomy. The medicine is also contraindicated in breastfeeding mothers and individuals known to be CYP2D6 ultra-rapid metabolizers due to the risk of life-threatening morphine toxicity. Patients must not use this medication if they have significant respiratory depression, severe asthma, gastrointestinal obstruction (paralytic ileus), or if they are currently taking Monoamine Oxidase Inhibitors (MAOIs).

Populations Requiring Conditional or Restricted Use

The drug is permitted for adults (18 years and older). For adolescents (12 to 18 years), use is for short-term, acute moderate pain not relieved by other options. Use is not recommended for adolescents with compromised respiratory function. Caution is required for patients with severe hepatic impairment or severe renal impairment due to the risk of accumulation. Pregnant women must be advised of the risk of Neonatal Opioid Withdrawal Syndrome (NOWS) if the drug is used regularly.

Interactions with other medicines and products

Concomitant use of this product with alcohol or other Central Nervous System (CNS) depressants (e.g., benzodiazepines, other opioids, sedatives, hypnotics, general anesthetics, tranquilizers) carries a major risk for profound sedation, respiratory depression, coma, and death. Such combinations are generally reserved for patients where alternative options are inadequate.

This medication should not be used in combination with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping MAOI treatment, due to the risk of severe adverse reactions including opioid toxicity and Serotonin Syndrome.

The metabolism of the codeine component is affected by drugs that inhibit or induce Cytochrome P450 (CYP) enzymes, particularly CYP2D6 and CYP3A4. Interactions with CYP modulators, such as certain antibiotics (e.g., rifampin, erythromycin) or antidepressants, can alter codeine's conversion to its active metabolite, morphine, impacting efficacy or safety.

The acetaminophen component is known to interact with warfarin and other anticoagulants, potentially increasing the risk of bleeding. Patients must also strictly avoid taking this medicine with any other products containing acetaminophen to prevent liver toxicity. Additionally, use with mixed opioid agonist/antagonists (e.g., butorphanol) is not recommended as it may reduce the analgesic effect.

Codeine: Opioid Receptor Agonism Cascade

Codeine is an opioid prodrug that undergoes O-demethylation, primarily catalyzed by the cytochrome P450 isoenzyme CYP2D6, to its active metabolite, morphine. Morphine acts as an agonist at the mu-opioid receptors (mu-OR) in the central nervous system (CNS). The activation of these G-protein coupled receptors leads to the inhibition of adenylate cyclase, resulting in decreased intracellular cyclic adenosine monophosphate ( cAMP) levels. This intracellular cascade modulates cellular excitability by promoting K^+ efflux and inhibiting Ca^2+ influx, which subsequently reduces the release of nociceptive neurotransmitters from the presynaptic terminal.

Acetaminophen: Central COX Enzyme Inhibition

Acetaminophen's mechanism is distinct and predominantly central. It acts by inhibiting cyclooxygenase (COX) activity, primarily within the CNS, thereby reducing the synthesis of prostaglandins. The inhibition of COX enzymes, which may include COX-3 and peroxidases, results in altered signaling pathways within the central nervous system.

Official Administration Guidelines

Property	Description
Route of administration	The medication is approved for oral administration only, available in solid (tablet) and liquid (solution/elixir) forms.
Standard Adult Dosing Regimen	The typical single dose is 1 to 2 tablets (based on combination strength) or 15 milliliters (mL) of the oral solution, administered as needed for discomfort.
Frequency and Daily Maximums	Doses are typically taken every 4 hours as needed, but the total intake of Acetaminophen from all sources must not exceed 4,000 mg in a 24-hour period.
Duration Principle	Official guidelines emphasize using the lowest effective dosage for the shortest duration to meet treatment goals. Guidance advises limiting treatment to 3 days.
Age-Group Administration Rules	This combination is contraindicated (should not be used) in children under 12 years of age and in adolescents under 18 following tonsillectomy or adenoidectomy. Dosing may require reduction in older adults.
Preparation and Procedural Specifics	Liquid forms must be shaken well before measurement, and a marked measuring device must be used for accurate dosing. If taking regularly, a missed dose is taken when remembered, but skipped if nearly time for the next dose. Discontinuation after prolonged use requires the dose to be tapered gradually.

---

This instruction map defines the precise framework for using the combination product. The official protocol governs the administration route, sets critical maximum dose limits for both active ingredients, and mandates specific restrictions based on age and treatment duration, ensuring a standardized approach to its intake.

Research Evidence / Overview of Studies for Dafalgan Codeine (Acetaminophen, Codeine)

This section describes the types of research that was studied for the Acetaminophen/Codeine combination, focusing on the research structure, and what the findings describe patterns observed in the studies, while maintaining a strictly neutral, non-clinical perspective.

---

Evidence for Use in Mild to Moderate Acute Pain

Research exploring short-term symptom changes related to acute pain consists of Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were used in research exploring how symptoms change over time in adults following procedures such as dental extractions or minor surgeries. Researchers monitored outcomes related to physical discomfort and the need for additional analgesic medication.

Findings describe patterns observed in the studies when compared to an inactive placebo. However, research also examined comparisons against non-opioid medications (like NSAIDs), and findings were mixed. Because the rate at which individuals process the codeine component may vary genetically, the research describes that the resultant changes in pain metrics can be unpredictable across different patients. Evidence is limited regarding the incremental benefit of low-dose codeine when added to Acetaminophen alone in certain acute pain situations.

---

Evidence for Symptomatic Relief of Disruptive Cough

The evidence structure for the combination’s use in cough is based on a limited number of Randomized Controlled Trials and related Systematic Reviews. Studies explored outcomes linked to inflammatory or irritative states by monitoring measures of cough frequency and severity. The research describes that the patterns of cough symptom change appear to be limited or mixed in some of the studies reviewed. Furthermore, there is a persistent lack of evidence to establish patterns of measured symptom changes related to the very low-dose codeine preparations for both pain and cough.

---

Evidence in Specialized Populations

Evidence is limited for pediatric patients, and the use in this group has been subject to specific advisories from international regulatory bodies. Studies observed a relationship between metabolism variability and unpredictable patterns in measured symptom changes in children. Research also explored patterns in older adults and monitored the transfer of the active drug components in women breastfeeding.

Common questions about Dafalgan Codeine (Acetaminophen,Codeine) (FAQ)

---

Q: Does this drug interact with oral contraceptives?

Official documents indicate that the metabolism of this medicine is influenced by specific liver enzymes, known as CYP450 3A4 and 2D6. Although regulatory information may not list every potential drug, it is important that a healthcare provider is aware of all medications being taken, including oral contraceptives, due to this potential enzyme interaction.

---

Q: Can it cause mood changes like euphoria or sadness?

Yes, official product information lists specific changes in mood as possible adverse reactions. These reported effects include both euphoria, which is an elevated feeling of well-being, and dysphoria, which is a feeling of unease or sadness.

---

Q: How does this medication affect lab tests, such as blood work?

Regulatory sources state that the codeine component may increase certain readings in blood work, such as serum amylase levels. Additionally, the acetaminophen component has been described as potentially causing false-positive results in specific tests for urinary 5-hydroxyindoleacetic acid.

---

Q: Is it possible to become tolerant to the pain relief?

Yes, official warnings note that tolerance may develop with repeated use of this narcotic-containing medication. Tolerance means that over time, a higher dose may be required to achieve the same level of pain relief.

---

Q: Can this medicine cause a dry mouth?

Dry mouth has been reported as an adverse reaction in the official prescribing information. This is listed among the possible effects related to the gastrointestinal system.

---

Q: Is this medicine suitable for mild or moderate inflammatory pain?

Official indications state the medicine is for the relief of mild to moderate pain in general, without specifying the type of pain. The regulatory label describes the acetaminophen component as a non-opioid analgesic and antipyretic.

---

Q: Will it interact with my blood pressure medication?

The codeine component has been observed to cause peripheral vasodilation, which may result in orthostatic hypotension (a drop in blood pressure when standing). If taking blood pressure medication, it is important to discuss potential risks with a healthcare professional before use.

---

Q: How is the dose adjusted for poor metabolizers of codeine?

Studies and official information indicate that individuals categorized as 'poor metabolizers' do not convert codeine into its active form (morphine) as completely as others. This variability in metabolism may result in inadequate pain relief. Decisions regarding treatment for poor metabolizers, including alternative options, are made by a healthcare professional.

---

Official Storage and Disposal Statements

Scope Item	Regulatory Requirement
Storage Temperature	Store at controlled room temperature between 20 C and 25 C (68 F and 77 F).
Environmental Protection	Keep away from excess heat and moisture; do not store in the bathroom or above a kitchen sink.
Packaging	Keep in the container it came in and ensure the container is tightly closed.
Child-Safety Storage	Must be stored securely out of the sight and reach of children and in a safe place to prevent accidental ingestion or misuse of the controlled substance.
Disposal Instructions	Unused or expired product must be disposed of promptly. Utilize a medicine take-back program or DEA-registered collector as the preferred method.
Household Disposal	If take-back options are unavailable, the product must be mixed with an unpalatable substance (e.g., dirt, coffee grounds), placed in a sealed bag, and put into household trash. All personal information must be deleted from the label before discarding the empty container.